<?xml version="1.0" encoding="UTF-8"?>
<p id="Par47">Around 30,000 cases of Lyme disease are reported each year to the US Centers for Disease Control (CDC); however, it is likely that the actual number of cases each year is closer to 300,000 in the USA [
 <xref ref-type="bibr" rid="CR129">129</xref>]. Wang et al. engineered an anti-
 <italic>Borrelia burgdorferi</italic> DMAb candidate expressing a transmission-blocking antibody targeting OspA [
 <xref ref-type="bibr" rid="CR130">130</xref>]. Initial expression of the wt-DMAb averaged 5.7 μg/mL, and sequence optimizations further increased expression to 6.7 μg/mL. The modified DMAb retained bactericidal activity comparable to the original DMAb and recombinant parent mAb. Both the wt-DMAb and modified DMAb were protective against 
 <italic>B. burgdorferi</italic> challenge in mice. This supports the potential for a DMAb approach to protect against Lyme disease transmission from tick to host.
</p>
